CervoMed Inc.

CervoMed Inc.

CRVO·NASDAQ

$5.50

-0.36%
HealthcareBiotechnology

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

At a Glance

Live Snapshot
Market Cap$50.89M
EPS-2.0200
P/E Ratio-1.16
Earnings Date03/16/2026

crvo

Additional Paid-In Capital

Last Annual Value

109.87M

3-Year CAGR

-13%

5-Year CAGR

%

10-Year CAGR

%

CervoMed Inc.

CervoMed Inc. Competitors Analysis of Additional Paid-In Capital

CRVO · NASDAQ
CompanyAdditional Paid-In Capital
CAGR 3Y
CAGR 5Y
CAGR 10Y
CRVO logo
CervoMed Inc.
NASDAQ:CRVO
109.87M
21.1%-7.8%4.7% 
290.93M
6.4%7.4%N/A
783.89M
3.0%3.6%10.7%
35.14M
85.6%56.4%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
773.79M
12.0%10.4%N/A
CLNN logo
Clene Inc.
NASDAQ:CLNN
290.53M
4.3%10.6%N/A
500.21M
3.2%4.3%N/A
12.83M
5.9%12.3%187.6%
0.00
N/AN/AN/A
551.08M
1.0%3.0%N/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
548.13M
5.4%6.1%13.1%
CervoMed Inc.

CervoMed Inc. Fair Value Envelope

CRVO · NASDAQ

Our analysis suggests that CRVO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.5, this represents a potential HIDDEN relative to our calculated worth for CervoMed Inc..

Intrinsic Value
Current Price: $5.5